Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells

Hong Nu Yu; Eun Mi Noh; Young Rae Lee; Si Gyun Roh; Eun Kyung Song; Myung Kwan Han; Yong Chul Lee; In Kyong Shim; Seung Jin Lee; Sung Hoo Jung; Jong Suk Kim; Hyun Jo Youn

doi:10.1016/j.bbrc.2008.09.111

Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells

Hong Nu Yu
, Eun Mi Noh
, Young Rae Lee
, Si Gyun Roh
, Eun Kyung Song
, Myung Kwan Han
, Yong Chul Lee
, In Kyong Shim
, Seung Jin Lee
, Sung Hoo Jung
, Jong Suk Kim^*
, Hyun Jo Youn

^*Corresponding author for this work

Department of Medicine

Research output: Contribution to journal › Journal article › peer-review

25 Scopus citations

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) ligands have been identified as a potential source of therapy for human cancers. However, PPARγ ligands have a limitation for breast cancer therapy, since estrogen receptor α (ER_α) negatively interferes with PPARγ signaling in breast cancer cells. Here we show that ER_α inhihits PPARγ transactivity and ER_α-mediated inhibition of PPARγ transactivity is blocked by tamoxifen, an estrogen receptor blocker. The activation of ER_α with 17-β-estradiol blocked PPRE transactivity induced by troglitazone, a PPARγ ligand, indicating the resistance of ER_α-positive breast cancer cells to troglitazone. Indeed, troglitazone inhibited the growth of ER_α-negative MDA-MB-231 cells more than that of ER_α-positive MCF-7 cells. Combination of troglitazone with tamoxifen led to a marked increase in growth inhibition of ER_α-positive MCF-7 cells compared to either agent alone. Our data indicates that troglitazone enhances the growth inhibitory activity of tamoxifen in ER_α-positive MCF-7 cells.

Original language	English
Pages (from-to)	242-247
Number of pages	6
Journal	Biochemical and Biophysical Research Communications
Volume	377
Issue number	1
DOIs	https://doi.org/10.1016/j.bbrc.2008.09.111
State	Published - 2008.12.5

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Apoptosis
Breast cancer
ER
PPARγ ligand
Tamoxifen

Quacquarelli Symonds(QS) Subject Topics

Biological Sciences

Access to Document

10.1016/j.bbrc.2008.09.111

Cite this

@article{8cc9e6983de8487394ee7a2a717fc4b9,

title = "Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells",

abstract = "Peroxisome proliferator-activated receptor γ (PPARγ) ligands have been identified as a potential source of therapy for human cancers. However, PPARγ ligands have a limitation for breast cancer therapy, since estrogen receptor α (ERα) negatively interferes with PPARγ signaling in breast cancer cells. Here we show that ERα inhihits PPARγ transactivity and ERα-mediated inhibition of PPARγ transactivity is blocked by tamoxifen, an estrogen receptor blocker. The activation of ERα with 17-β-estradiol blocked PPRE transactivity induced by troglitazone, a PPARγ ligand, indicating the resistance of ERα-positive breast cancer cells to troglitazone. Indeed, troglitazone inhibited the growth of ERα-negative MDA-MB-231 cells more than that of ERα-positive MCF-7 cells. Combination of troglitazone with tamoxifen led to a marked increase in growth inhibition of ERα-positive MCF-7 cells compared to either agent alone. Our data indicates that troglitazone enhances the growth inhibitory activity of tamoxifen in ERα-positive MCF-7 cells.",

keywords = "Apoptosis, Breast cancer, ER, PPARγ ligand, Tamoxifen",

author = "Yu, \{Hong Nu\} and Noh, \{Eun Mi\} and Lee, \{Young Rae\} and Roh, \{Si Gyun\} and Song, \{Eun Kyung\} and Han, \{Myung Kwan\} and Lee, \{Yong Chul\} and Shim, \{In Kyong\} and Lee, \{Seung Jin\} and Jung, \{Sung Hoo\} and Kim, \{Jong Suk\} and Youn, \{Hyun Jo\}",

year = "2008",

month = dec,

day = "5",

doi = "10.1016/j.bbrc.2008.09.111",

language = "English",

volume = "377",

pages = "242--247",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

number = "1",

}

TY - JOUR

T1 - Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells

AU - Yu, Hong Nu

AU - Noh, Eun Mi

AU - Lee, Young Rae

AU - Roh, Si Gyun

AU - Song, Eun Kyung

AU - Han, Myung Kwan

AU - Lee, Yong Chul

AU - Shim, In Kyong

AU - Lee, Seung Jin

AU - Jung, Sung Hoo

AU - Kim, Jong Suk

AU - Youn, Hyun Jo

PY - 2008/12/5

Y1 - 2008/12/5

N2 - Peroxisome proliferator-activated receptor γ (PPARγ) ligands have been identified as a potential source of therapy for human cancers. However, PPARγ ligands have a limitation for breast cancer therapy, since estrogen receptor α (ERα) negatively interferes with PPARγ signaling in breast cancer cells. Here we show that ERα inhihits PPARγ transactivity and ERα-mediated inhibition of PPARγ transactivity is blocked by tamoxifen, an estrogen receptor blocker. The activation of ERα with 17-β-estradiol blocked PPRE transactivity induced by troglitazone, a PPARγ ligand, indicating the resistance of ERα-positive breast cancer cells to troglitazone. Indeed, troglitazone inhibited the growth of ERα-negative MDA-MB-231 cells more than that of ERα-positive MCF-7 cells. Combination of troglitazone with tamoxifen led to a marked increase in growth inhibition of ERα-positive MCF-7 cells compared to either agent alone. Our data indicates that troglitazone enhances the growth inhibitory activity of tamoxifen in ERα-positive MCF-7 cells.

AB - Peroxisome proliferator-activated receptor γ (PPARγ) ligands have been identified as a potential source of therapy for human cancers. However, PPARγ ligands have a limitation for breast cancer therapy, since estrogen receptor α (ERα) negatively interferes with PPARγ signaling in breast cancer cells. Here we show that ERα inhihits PPARγ transactivity and ERα-mediated inhibition of PPARγ transactivity is blocked by tamoxifen, an estrogen receptor blocker. The activation of ERα with 17-β-estradiol blocked PPRE transactivity induced by troglitazone, a PPARγ ligand, indicating the resistance of ERα-positive breast cancer cells to troglitazone. Indeed, troglitazone inhibited the growth of ERα-negative MDA-MB-231 cells more than that of ERα-positive MCF-7 cells. Combination of troglitazone with tamoxifen led to a marked increase in growth inhibition of ERα-positive MCF-7 cells compared to either agent alone. Our data indicates that troglitazone enhances the growth inhibitory activity of tamoxifen in ERα-positive MCF-7 cells.

KW - Apoptosis

KW - Breast cancer

KW - ER

KW - PPARγ ligand

KW - Tamoxifen

UR - https://www.scopus.com/pages/publications/54449088704

U2 - 10.1016/j.bbrc.2008.09.111

DO - 10.1016/j.bbrc.2008.09.111

M3 - Journal article

C2 - 18835379

AN - SCOPUS:54449088704

SN - 0006-291X

VL - 377

SP - 242

EP - 247

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 1

ER -

Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells

Abstract

UN SDGs

Keywords

Quacquarelli Symonds(QS) Subject Topics

Access to Document

Other files and links

Fingerprint

Cite this